Optimal Empiric Treatment for Klebsiella pneumoniae Infections in Short-Stay ICU Patients During Continuous Renal Replacement Therapy: Results from a Population Pharmacokinetic/Pharmacodynamic Analysis

References

• Bellomo R, Kellum JA, Ronco C, et al. Acute kidney injury in sepsis. Intensive Care Med. 2017;43(6):816–828. doi:10.1007/s00134-017-4755-728364303
   PubMed Web of Science ®Google Scholar
• Uchino S, Bellomo R, Morimatsu H, et al. Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators. Intensive Care Med. 2007;33(9):1563–1570. doi:10.1007/s00134-007-0754-417594074
   PubMed Web of Science ®Google Scholar
• Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med. 2009;37(3):840–851. doi:10.1097/CCM.0b013e3181961bff19237886
   PubMed Web of Science ®Google Scholar
• Choi G, Gomersall CD, Tian Q, Joynt GM, Freebairn R, Lipman J. Principles of antibacterial dosing in continuous renal replacement therapy. Crit Care Med. 2009;37(7):2268–2282. doi:10.1097/CCM.0b013e3181aab3d019487930
   PubMed Web of Science ®Google Scholar
• Xu L, Sun X, Ma X. Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae. Ann Clin Microbiol Antimicrob. 2017;16(1):18. doi:10.1186/s12941-017-0191-328356109
   PubMed Web of Science ®Google Scholar
• Giannella M, Trecarichi EM, De Rosa FG, et al. Risk factors for carbapenem-resistant Klebsiella pneumoniae bloodstream infection among rectal carriers: a prospective observational multicentre study. Clin Microbiol Infect. 2014;20(12):1357–1362. doi:10.1111/1469-0691.1274724980276
   PubMed Web of Science ®Google Scholar
• Zheng B, Xu H, Lv T, et al. Stool samples of acute diarrhea inpatients as a reservoir of ST11 hypervirulent KPC-2-producing Klebsiella pneumoniae. mSystems. 2020;5(3). doi:10.1128/mSystems.00498-20.
   Web of Science ®Google Scholar
• Lin MY, Lyles-Banks RD, Lolans K, et al. The importance of long-term acute care hospitals in the regional epidemiology of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae. Clin Infect Dis. 2013;57(9):1246–1252. doi:10.1093/cid/cit50023946222
   PubMed Web of Science ®Google Scholar
• Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34(6):1589–1596. doi:10.1097/01.CCM.0000217961.75225.E916625125
   PubMed Web of Science ®Google Scholar
• Jamal JA, Economou CJ, Lipman J, Roberts JA. Improving antibiotic dosing in special situations in the ICU: burns, renal replacement therapy and extracorporeal membrane oxygenation. Curr Opin Crit Care. 2012;18(5):460–471. doi:10.1097/MCC.0b013e32835685ad22820155
   PubMed Web of Science ®Google Scholar
• Nielsen EI, Friberg LE. Pharmacokinetic-pharmacodynamic modeling of antibacterial drugs. Pharmacol Rev. 2013;65:1053–1090. doi:10.1124/pr.111.00576923803529
   PubMed Web of Science ®Google Scholar
• Rodloff AC, Goldstein EJ, Torres A. Two decades of imipenem therapy. J Antimicrob Chemother. 2006;58(5):916–929. doi:10.1093/jac/dkl35416997845
   PubMed Web of Science ®Google Scholar
• Bao H, Lv Y, Wang D, Xue J, Yan Z. Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial. Eur J Clin Microbiol Infect Dis. 2017;36(3):459–466. doi:10.1007/s10096-016-2819-127796647
   PubMed Web of Science ®Google Scholar
• Ng TM, Khong WX, Harris PN, et al. Empiric piperacillin-tazobactam versus carbapenems in the treatment of bacteraemia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae. PLoS One. 2016;11(4):e0153696. doi:10.1371/journal.pone.015369627104951
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, 30th edition. Available from: http://www.clsi.org/. Accessed January 21, 2020.
   Google Scholar
• Li S, Xie F. Population pharmacokinetics and simulations of imipenem in critically ill patients undergoing continuous renal replacement therapy. Int J Antimicrob Agents. 2019;53(1):98–105. doi:10.1016/j.ijantimicag.2018.10.00630626495
   PubMed Web of Science ®Google Scholar
• Bue M, Sou T, Okkels ASL, et al. Population pharmacokinetics of piperacillin in plasma and subcutaneous tissue in patients on continuous renal replacement therapy. Int J Infect Dis. 2020;92:133–140. doi:10.1016/j.ijid.2020.01.01031978581
   PubMed Web of Science ®Google Scholar
• Lewis SJ, Kays MB, Mueller BA. Use of monte carlo simulations to determine optimal carbapenem dosing in critically ill patients receiving prolonged intermittent renal replacement therapy. J Clin Pharmacol. 2016;56(10):1277–1287. doi:10.1002/jcph.72726919659
   PubMed Web of Science ®Google Scholar
• Asin-Prieto E, Rodriguez-Gascon A, Troconiz IF, et al. Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis. J Antimicrob Chemother. 2014;69(1):180–189. doi:10.1093/jac/dkt30423908259
   PubMed Web of Science ®Google Scholar
• Turnidge JD. The pharmacodynamics of beta-lactams. Clin Infect Dis. 1998;27(1):10–22. doi:10.1086/5146229675443
   PubMed Web of Science ®Google Scholar
• Roberts JA, Kirkpatrick CM, Roberts MS, Dalley AJ, Lipman J. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int J Antimicrob Agents. 2010;35(2):156–163. doi:10.1016/j.ijantimicag.2009.10.00820018492
   PubMed Web of Science ®Google Scholar
• Roberts JA, Paul SK, Akova M, et al. DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis. 2014;58(8):1072–1083. doi:10.1093/cid/ciu02724429437
   PubMed Web of Science ®Google Scholar
• Beumier M, Casu GS, Hites M, et al. Elevated beta-lactam concentrations associated with neurological deterioration in ICU septic patients. Minerva Anestesiol. 2015;81:497–506.25220556
   PubMed Web of Science ®Google Scholar
• Lamoth F, Erard V, Asner S, Buclin T, Calandra T, Marchetti O. High imipenem blood concentrations associated with toxic encephalopathy in a patient with mild renal dysfunction. Int J Antimicrob Agents. 2009;34(4):386–388. doi:10.1016/j.ijantimicag.2009.06.00119596561
   PubMed Web of Science ®Google Scholar
• Drusano GL, Preston SL, Hardalo C, et al. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob Agents Chemother. 2001;45(1):13–22. doi:10.1128/AAC.45.1.13-22.200111120938
   PubMed Web of Science ®Google Scholar
• Bradley JS, Dudley MN, Drusano GL. Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulation. Pediatr Infect Dis J. 2003;22(11):982–992. doi:10.1097/01.inf.0000094940.81959.1414614372
   PubMed Web of Science ®Google Scholar
• Abdulall AK, Tawfick MM, El Manakhly AR, El Kholy A. Carbapenem-resistant gram-negative bacteria associated with catheter-related bloodstream infections in three intensive care units in Egypt. Eur J Clin Microbiol Infect Dis. 2018;37(9):1647–1652. doi:10.1007/s10096-018-3294-729936619
   PubMed Web of Science ®Google Scholar
• Polemis M, Tryfinopoulou K, Giakkoupi P, Vatopoulos A. Eight-year trends in the relative isolation frequency and antimicrobial susceptibility among bloodstream isolates from Greek hospitals: data from the Greek electronic system for the surveillance of antimicrobial resistance - WHONET-Greece, 2010 to 2017. Euro Surveill. 2020;25(34). doi:10.2807/1560-7917.ES.2020.25.34.1900516
   Google Scholar
• Liu P, Li X, Luo M, et al. Risk factors for carbapenem-resistant klebsiella pneumoniae infection: a meta-analysis. Microb Drug Resist. 2018;24(2):190–198. doi:10.1089/mdr.2017.006128749714
   PubMed Web of Science ®Google Scholar
• Fish DN, Teitelbaum I, Abraham E. Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother. 2005;49(6):2421–2428. doi:10.1128/AAC.49.6.2421-2428.200515917542
   PubMed Web of Science ®Google Scholar
• Luther MK, Timbrook TT, Caffrey AR, Dosa D, Lodise TP, LaPlante KL. Vancomycin plus piperacillin-tazobactam and acute kidney injury in adults: a systematic review and meta-analysis. Crit Care Med. 2018;46(1):12–20. doi:10.1097/CCM.000000000000276929088001
   PubMed Web of Science ®Google Scholar
• van der Werf TS, Mulder PO, Zijlstra JG, Uges DR, Stegeman CA. Pharmacokinetics of piperacillin and tazobactam in critically ill patients with renal failure, treated with continuous veno-venous hemofiltration (CVVH). Intensive Care Med. 1997;23(8):873–877. doi:10.1007/s0013400504249310805
   PubMed Web of Science ®Google Scholar